Quantcast

Latest Tardive dyskinesia Stories

2011-06-23 07:30:00

SAN DIEGO, June 23, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854.

2011-04-13 07:42:03

Results of the first, long-term clinical trial show the investigational drug safinamide may reduce dyskinesia (involuntary movements) in mid-to-late stage Parkinson’s disease.

2011-04-12 15:01:21

Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease.

2011-04-11 07:00:00

TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.

2011-04-05 08:00:00

SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854.

2010-12-01 08:00:00

COMMACK, N.Y., Dec. 1, 2010 /PRNewswire/ -- The law office of Rudolph F.X. Migliore, P.C.


Word of the Day
shotta
  • An armed gangster.
The word 'shotta' is an alteration of 'shooter'.